Clinical Trial Update: Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sulodexide (VESSEL) for preventing recurrent venous thromboembolism. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• VESSEL (sulodexide)

Snippet

Sponsor: Arianna Anticoagulazione Foundation | Conditions: Venous Thromboembolism, Anticoagulant | Phase 3 | Status: RECRUITING